WellDoc scores $22 million for BlueStar diabetes management platform

WellDoc, whose BlueStar technology is focused on adults with Type 2 diabetes, has drawn $22 million in a Series B round of funding from Samsung Ventures and existing investor Merck Global Health Innovation Fund. The company will use the money to continue commercialization and accelerate adoption of BlueStar. Adage Capital Management, Excel Venture Management, Alexandria Venture Investments and Hudson River Capital Partners also participated in the funding round. Patient Engagement read more
Source: Healthcare IT News - Category: Information Technology Authors: Tags: Online Only Clinical Medical Devices Mobile Patient Engagement Source Type: news